CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 9, 2009--
POZEN Inc. (NASDAQ: POZN), today announced the election of
Angela M. Larson to its board of directors at the Annual Meeting of
Stockholders held on June 3, 2009. Ms. Larson is President, Larson Pharm
Consult, LLC, a pharmaceutical industry focused corporate development
business strategy consulting firm, and President, Fierce Fun Toys, LLC,
a toy manufacturer and retailer. Previously, Ms. Larson was an equity
research analyst focused on the Specialty Pharmaceutical sector for a
number of large and small financial firms, including
SmithBarney/CitiGroup, Susquehanna International Group, PaineWebber, and
C.E. Unterberg Towbin. While at Unterberg Towbin, she became the
Director of Research and a member of the company's operating committee
which was responsible for firm strategy, budgeting, and forecasting.
Dr. John R. Plachetka, POZEN’s Chairman, President, and CEO said “We are
pleased to welcome Angela to the POZEN board of directors. Her years of
Wall Street experience in evaluating business strategies will complement
and expand the strength and capabilities of our board.”
About POZEN
POZEN is a pharmaceutical company committed to developing therapeutic
advancements for diseases with unmet medical needs where it can improve
efficacy, safety, and/or patient convenience. POZEN’s efforts are
focused primarily on the development of pharmaceutical products for the
treatment of acute and chronic pain and other pain-related conditions.
POZEN has development and commercialization alliances with
GlaxoSmithKline for Treximet®, which was
approved in 2008 by the United States Food and Drug Administration for
the acute treatment of migraine attacks, with or without aura, in
adults, and with AstraZeneca for proprietary fixed dose combinations of
naproxen with the proton pump inhibitor esomeprazole magnesium in a
single tablet for conditions such as osteoarthritis and rheumatoid
arthritis in patients who are at risk for developing NSAID-associated
gastric ulcers. The Company’s common stock is traded on The NASDAQ Stock
Market under the symbol “POZN”. For detailed company information,
including copies of this and other press releases, see POZEN’s website: www.pozen.com.
Statements included in this press release that are not historical in
nature are “forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act of
1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements, which
are based on management’s current expectations and are subject to a
number of risks and uncertainties, including, but not limited to, our
failure to successfully commercialize our product candidates; costs and
delays in the development and/or FDA approval of our product candidates,
including as a result of the need to conduct additional studies, or the
failure to obtain such approval of our product candidates, including as
a result of changes in regulatory standards or the regulatory
environment during the development period of any of our product
candidates; uncertainties in clinical trial results or the timing of
such trials, resulting in, among other things, an extension in the
period over which we recognize deferred revenue or our failure to
achieve milestones that would have provided us with revenue; our
inability to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products, including our dependence on
GlaxoSmithKline for the sales and marketing of Treximet; competitive
factors; our inability to protect our patents or proprietary rights and
obtain necessary rights to third party patents and intellectual property
to operate our business; our inability to operate our business without
infringing the patents and proprietary rights of others; general
economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events, including those discussed herein and in
our Quarterly Report on Form 10-Q for the period ended March 31, 2009.
We do not intend to update any of these factors or to publicly announce
the results of any revisions to these forward-looking statements.
Source: POZEN Inc.
POZEN Inc.
Bill Hodges, Chief Financial Officer
919-913-1030
